Modeling breast cancer using CRISPR/Cas9-mediated engineering of human breast organoids
- Dekkers, JF; Whittle, JR; Vaillant, F; Chen, HR; Dawson, C; Liu, K; Geurts, M; Herold, MJ; Clevers, H; Lindeman, GJ; Visvader, JE;
Publication Year 2020-05-01, Volume 112, Issue #5, Page 540-544
- Journal Title
- Journal of the National Cancer Institute
- Breast cancer is characterized by histological and functional heterogeneity, posing a clinical challenge for patient treatment. Emerging evidence suggests that the distinct subtypes reflect the repertoire of genetic alterations and the target cell. However, the precise initiating events that predispose normal epithelium to neoplasia are poorly understood. Here we demonstrate that breast epithelial organoids can be generated from human reduction mammoplasties (12 out of 12 donors), thus creating a tool to study the clonal evolution of breast cancer. To recapitulate de novo oncogenesis, we exploited CRISPR/Cas9 for targeted knock-out of four breast cancer-associated tumor suppressor genes (P53, PTEN, RB1, NF1) in mammary progenitor cells from six donors. Mutant organoids gained long-term culturing capacity and formed ER+ luminal tumors upon transplantation into mice for 1 out of 6 P53/PTEN/RB1-mutated and 3 out of 6 P53/PTEN/RB1/NF1-mutated lines. These organoids responded to endocrine therapy or chemotherapy, supporting the potential utility of this model to enhance our understanding of the molecular events that culminate in specific subtypes of breast cancer.
- Oxford Academic
- WEHI Research Division(s)
- Cancer Biology And Stem Cells; Blood Cells And Blood Cancer
- PubMed ID
- Link To PubMed Central Version
- Publisher's Version
- Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2019-10-23 02:22:51Last Modified: 2021-05-12 01:13:24